You have 9 free searches left this month | for more free features.

Metastatic Salivary Gland Cancer

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

GENE EXPRESSION PROFILING IN A VALIDATION COHORT OF LOCALLY

Not yet recruiting
  • Salivary Gland Cancer
  • Observation
  • (no location specified)
Oct 13, 2023

Gland, Salivary Gland Cancers Trial in Houston (Sacituzumab Govitecan)

Not yet recruiting
  • Gland
  • Salivary Gland Cancers
  • Sacituzumab Govitecan
  • Houston, Texas
    M D Anderson Cancer Center
May 22, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage IV Major Salivary Gland Cancer AJCC v8 Trial in

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +5 more
  • Pembrolizumab
  • Pemetrexed Disodium
  • Scottsdale, Arizona
  • +2 more
Mar 15, 2022

Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in

Recruiting
  • Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
  • +2 more
  • Beijing, Beijing, China
  • +1 more
Nov 21, 2023

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48)
  • +3 more
  • (no location specified)
Jun 9, 2023

Salivary Gland Cancer Trial in Seoul (docetaxel plus Cisplatin)

Active, not recruiting
  • Salivary Gland Cancer
  • docetaxel plus Cisplatin
  • Seoul, Gangnamgu, Korea, Republic of
    Samsung Medical Center
Aug 16, 2021

Locally Advanced Salivary Gland Carcinoma, Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma Trial

Not yet recruiting
  • Locally Advanced Salivary Gland Carcinoma
  • +3 more
  • Biopsy
  • +3 more
  • (no location specified)
Jan 10, 2023

Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 Trial

Recruiting
  • Metastatic Salivary Gland Carcinoma
  • +4 more
  • New York, New York
    Memorial Sloane Kettering Cancer Center
Jan 11, 2023

Salivary Gland Carcinoma, Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in Boston (9-ING-41, Carboplatin)

Withdrawn
  • Salivary Gland Carcinoma
  • +3 more
  • Boston, Massachusetts
    Dana-Farber Cancer Institute
Feb 5, 2022

Prostatic Tumors, Castration-Resistant, Tumors by Histologic Type, Tumors, Prostate Trial in United States (P-PSMA-101 CAR-T

Active, not recruiting
  • Prostatic Neoplasms, Castration-Resistant
  • +16 more
  • Duarte, California
  • +9 more
Nov 15, 2022

Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharynx

Active, not recruiting
  • Head and Neck Squamous Cell Carcinoma
  • +14 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 11, 2022

Adenoid Cystic Carcinoma, Salivary Gland Cancer Trial in United States (Lenvatinib, Pembrolizumab)

Recruiting
  • Adenoid Cystic Carcinoma
  • Salivary Gland Cancer
  • Miami, Florida
  • +7 more
Oct 26, 2022

Salivary Gland Cancer Trial in Cincinnati (Amivantamab)

Recruiting
  • Salivary Gland Cancer
  • Cincinnati, Ohio
    University of Cincinnati Medical Center
Aug 5, 2022

Salivary Gland Cancer, Metastatic, Advanced Trial in Toronto (Selinexor, EGFR or HER2 Inhibitor, FGFR Inhibitor)

Recruiting
  • Salivary Gland Cancer
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Feb 18, 2022

Salivary Gland Carcinoma, Metastatic Cancer, Recurrent Cancer Trial in France (Nivolumab)

Completed
  • Salivary Gland Carcinoma
  • +2 more
  • Bordeaux, France
  • +10 more
Jan 10, 2022

PSMA-PET Imaging of Salivary Gland Tumours and Other Rare

Recruiting
  • Salivary Gland Tumor
  • Rare Malignant Neoplasm
  • 68-Ga PSMA PET scan
  • Singapore, Singapore
    National Cancer Centre Singapore
Oct 11, 2022

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

Salivary Gland Cancer, Salivary Duct Carcinoma, Adenoid Cystic Carcinoma Trial in Nijmegen (Lutetium-177-PSMA-I&T)

Recruiting
  • Salivary Gland Cancer
  • +2 more
  • Nijmegen, Gelderland, Netherlands
    Radboudumc
Oct 27, 2022

Salivary Gland Cancer, HER2 Gene Mutation Trial in Boston (Ado-trastuzumab (T) emtansine (T-DM1), Standard of Care Radiotherapy,

Recruiting
  • Salivary Gland Cancer
  • HER2 Gene Mutation
  • Ado-trastuzumab (T) emtansine (T-DM1)
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 2, 2023

Prostate Cancer, Prostate Cancer Metastatic, Prostatic Tumor Trial in Vancouver (18F-DCFPyL PET/CT scan, Placebo drink, MSG

Completed
  • Prostate Cancer
  • +2 more
  • 18F-DCFPyL PET/CT scan
  • +2 more
  • Vancouver, British Columbia, Canada
    BC Cancer
Nov 15, 2021

Metastatic Breast Carcinoma, Locally Advanced Breast Cancer, Cancer of Pancreas Trial in Brussels (68GaNOTA-Anti-HER2 VHH1)

Recruiting
  • Metastatic Breast Carcinoma
  • +13 more
  • 68GaNOTA-Anti-HER2 VHH1
  • Brussels, Brussel, Belgium
    Uz Brussel
Dec 17, 2021

Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With

Completed
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +35 more
  • PI3K inhibitor BKM120
  • cetuximab
  • Chicago, Illinois
    University of Chicago Comprehensive Cancer Center
Sep 14, 2021

Salivary Gland Carcinoma Trial in United States (Goserelin Acetate, Pembrolizumab)

Recruiting
  • Salivary Gland Carcinoma
  • Chicago, Illinois
  • +6 more
Sep 22, 2022

Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell

Active, not recruiting
  • Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
  • +29 more
  • Cytology specimen
  • Laboratory biomarker analysis
  • Philadelphia, Pennsylvania
    Thomas Jefferson University
Aug 31, 2021